GlassScriptPhysician profile
Sayed Jovkar
NPI 1316092802
$2,553.28
in general payments reported to CMS, 2019-2025
21 companies · $269 in 2025
The $269 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,279 · 2020: $101 · 2021: $319 · 2022: $313 · 2023: $117 · 2024: $156 · 2025: $269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $514 · Honoraria: $27.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $514.13 |
| Honoraria | $27.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $410.15 | 2019-2025 | |
| Alcon Vision LLC | $346.14 | 2019-2025 | Clareon, Clareon Panoptix Pro, Rocklatan |
| Aerie Pharmaceuticals, INC. | $288.89 | 2019-2021 | |
| Allergan, INC. | $279.14 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $220.65 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $189.92 | 2019-2023 | Cequa, Xelpros |
| Alexion Pharmaceuticals, INC. | $170.44 | 2019 | |
| Dompe US, INC. | $124.96 | 2024 | Oxervate |
| Hoffmann-La Roche Limited | $106.78 | 2019 | |
| Maculogix, INC. | $98.50 | 2019 | |
| Biotissue Holdings INC. | $79.75 | 2020 | |
| Johnson & Johnson Surgical Vision, INC. | $55.58 | 2019-2023 | Lipiflow System Activator (Disposable) |
| Oyster Point Pharma, INC. | $32.27 | 2022 | |
| Rxsight INC | $27.78 | 2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Horizon Therapeutics Plc | $25.04 | 2023 | Tepezza |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec USA, INC. | $21.78 | 2022 | |
| Eyevance Pharmaceuticals LLC | $17.70 | 2019 | |
| Bausch & Lomb Americas INC. | $16.10 | 2023 | Vyzulta |
| Abb Con-Cise Optical Group LLC | $15.08 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $13.79 | 2024 | Xdemvy |
| Glaukos Corporation | $12.84 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sayed Jovkar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.